To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.

This bill reauthorizes through FY2027 the Food and Drug Administration's Critical Path Public-Private Partnerships, which support medical product innovation, development, and safety.

[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7658 Introduced in House (IH)]

<DOC>






117th CONGRESS
  2d Session
                                H. R. 7658

 To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the 
               Critical Path Public-Private Partnerships.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                              May 3, 2022

 Mr. O'Halleran (for himself and Mrs. Lesko) introduced the following 
    bill; which was referred to the Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL


 
 To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the 
               Critical Path Public-Private Partnerships.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. REAUTHORIZATION OF THE CRITICAL PATH PUBLIC-PRIVATE 
              PARTNERSHIPS.

    Section 566(f) of the Federal Food, Drug, and Cosmetic Act (21 
U.S.C. 360bbb-5(f)) is amended by striking ``$6,000,000 for each of 
fiscal years 2018 through 2022'' and inserting ``$10,000,000 for each 
of fiscal years 2023 through 2027''.
                                 <all>